GSA Capital Partners LLP Sells 14,323 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

GSA Capital Partners LLP lowered its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 48.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,083 shares of the company’s stock after selling 14,323 shares during the quarter. GSA Capital Partners LLP’s holdings in Phathom Pharmaceuticals were worth $273,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Phathom Pharmaceuticals by 41.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock valued at $43,000 after acquiring an additional 722 shares during the last quarter. US Bancorp DE grew its holdings in shares of Phathom Pharmaceuticals by 28.6% during the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after purchasing an additional 1,166 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Phathom Pharmaceuticals by 42.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after buying an additional 2,987 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new position in shares of Phathom Pharmaceuticals in the first quarter valued at about $119,000. Finally, LVW Advisors LLC bought a new position in shares of Phathom Pharmaceuticals in the second quarter valued at about $133,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

PHAT has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Monday, August 12th. Needham & Company LLC restated a “buy” rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday, September 13th. Finally, The Goldman Sachs Group raised their price target on Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, August 9th.

Phathom Pharmaceuticals Stock Performance

Phathom Pharmaceuticals stock opened at $9.34 on Friday. The stock has a 50-day simple moving average of $15.65 and a 200 day simple moving average of $13.32. The stock has a market capitalization of $638.67 million, a P/E ratio of -1.64 and a beta of 0.72. Phathom Pharmaceuticals, Inc. has a 52 week low of $6.07 and a 52 week high of $19.71.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.